Skip to main content
. 2020 Apr 22;9(12):4160–4165. doi: 10.1002/cam4.3071

Figure 1.

Figure 1

Second choice after discontinuation of first‐line dasatinib (in red) or nilotinib (in green) for any reasons (panel A), for treatment failure (panel B) or intolerance (panel C). Second TKI bosutinib and ponatinib are blue and violet colored, respectively